Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for Patients With RAS-mutant, Microsatellite Stable, Metastatic Colorectal Cancer: a Prospective, Open-label, Single-arm, Phase II Trial

NCT06206096 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT06206096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06206096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for Patients With RAS-mutant, Microsatellite Stable, Metastatic Colorectal Cancer: a Prospective, Open-label, Single-arm, Phase II Trial
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
May 26, 2021
Completion date
December 31, 2025
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, colorectal neoplasms, microsatellite stable colorectal carcinoma, ras mutation